Evidence map›Paper›PMID 40356679›Full record

ReviewDrug design, development and therapy2025

A Natural Compound Methylnissolin: Physicochemical Properties, Pharmacological Activities, Pharmacokinetics and Resource Development.

Ziyang Lin, Mingjie Liang, Xianlong Zhang, Zhuo Cen, Fengxin Kang, Baien Liang, Ying Lai, Minyi Li, Tingting Duan, Junzheng Yang and 1 more

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ziyang LinThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0000-0001-7228-6851
Mingjie LiangGuangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
Xianlong ZhangThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Zhuo CenThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Fengxin KangGuangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
Baien LiangGuangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
Ying LaiGuangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
Minyi LiGuangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
Tingting DuanGuangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
Junzheng YangGuangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
Bo LiuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0000-0002-9539-2005

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methylnissolin (also known as Astrapterocarpan) is an isoflavonoid compound featuring a pterocarpan core structure. To date, leguminous plants of the genus

Indexed as

Antineoplastic Agents, PhytogenicBiological ProductsIsoflavonesAnimalsAnti-Inflammatory AgentsAntioxidantsDrug DevelopmentHumansMolecular StructureAnti-Inflammatory AgentsAntineoplastic Agents, PhytogenicAntioxidantsBiological ProductsIsoflavonesastragalus mongholicusastrapterocarpanmethylnissolinmethylnissolin-3-O-glucosidepharmacokineticspharmacological activity

Identifiers

PMID40356679
PMCPMC12068406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.